Tower Research Capital LLC (TRC) - AMYLYX PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of AMYLYX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$72,709
-21.0%
3,971
-6.9%
0.00%
-33.3%
Q2 2023$92,017
+170301.9%
4,266
+135.4%
0.00%
+50.0%
Q1 2023$54
-22.9%
1,812
-4.5%
0.00%
-33.3%
Q4 2022$70
-99.9%
1,898
-37.9%
0.00%
+200.0%
Q3 2022$86,000
+34.4%
3,058
-8.4%
0.00%0.0%
Q2 2022$64,000
+540.0%
3,340
+369.8%
0.00%
Q1 2022$10,0007110.00%
Other shareholders
AMYLYX PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,515,868$46,065,54315.30%
Alpha Wave Global, LP 853,262$15,623,2279.88%
Saturn V Capital Management LP 886,143$16,225,2786.79%
Ally Bridge Group (NY) LLC 272,690$4,992,9545.86%
Altium Capital Management LP 534,700$9,790,3575.11%
Boxer Capital, LLC 2,084,000$38,158,0402.03%
Octagon Capital Advisors LP 695,000$12,725,4501.96%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 295,000$5,398,5001.82%
Tri Locum Partners LP 282,862$5,179,2031.66%
Perceptive Advisors 2,688,873$49,233,2651.64%
View complete list of AMYLYX PHARMACEUTICALS INC shareholders